Relationships Between APOE, Type 2 Diabetes, and Cardiovascular Disease in Postmenopausal Women

Overview

Journal J Gerontol A Biol Sci Med Sci

Specialty Geriatrics

Date 2024 Oct 4

PMID 39364911

Authors

Michelle M Dunk

Ira Driscoll

Mark A Espeland

Kathleen M Hayden

Simin Liu

Rami Nassir

Ginny Natale

Aladdin H Shadyab

JoAnn E Manson

Jo Ann E Manson

Affiliations

Soon will be listed here.

Abstract

Background: The apolipoprotein E (APOE) ε4 allele, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) are well-established risk factors for dementia. Relationships between APOE and incidence of T2DM and CVD are not fully understood but may shed light on the mechanisms underlying dementia pathogenesis.

Methods: Postmenopausal women (N = 6 795) from the Women's Health Initiative hormone therapy clinical trial with APOE genotyping and no prior diagnosis of T2DM or CVD were included. We examined associations of APOE status (APOE2+ [ε2/ε2, ε2/ε3], APOE3 [ε3/ε3], and APOE4+ [ε4/ε4, ε3/ε4] carriers) with incidence of T2DM, coronary heart disease, stroke, and total CVD events using Cox regression. CVD outcomes were examined in baseline non-statin users and adjusted for statin initiation over follow-up to account for possible confounding by statins.

Results: Among all participants (mean age 66.7 ± 6.5 years, 100% non-Hispanic White), 451 (6.6%) were using statins at baseline. Over the follow-up (mean 14.9 and 16.0 years for T2DM and CVD, respectively), 1 564 participants developed T2DM and 1 578 developed CVD. T2DM incidence did not differ significantly by APOE status (ps ≥ .09). Among non-statin users, APOE4+ had higher incidence of total CVD (hazard ratio [95% confidence interval] = 1.18 [1.02-1.38], p = .03) compared with APOE3 carriers, but risks for coronary heart disease (1.09 [0.87-1.36], p = .47) and stroke (1.14 [0.91-1.44], p = .27) were not significantly elevated when examined individually. CVD outcomes did not differ between APOE2+ and APOE3 carriers (ps ≥ 0.11).

Conclusions: T2DM risk did not differ by APOE status among postmenopausal women, but APOE4+ carriers not using statins had an increased risk of total CVD events.

References

Mahley R . Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016; 94(7):739-46. PMC: 4921111. DOI: 10.1007/s00109-016-1427-y. View

Kypreos K, Karagiannides I, Fotiadou E, Karavia E, Brinkmeier M, Giakoumi S . Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J. 2009; 276(20):5720-8. DOI: 10.1111/j.1742-4658.2009.07301.x. View

de Frias C, Schaie K, Willis S . Hypertension moderates the effect of APOE on 21-year cognitive trajectories. Psychol Aging. 2014; 29(2):431-9. DOI: 10.1037/a0036828. View

Ward H, Mitrou P, Bowman R, Luben R, Wareham N, Khaw K . APOE genotype, lipids, and coronary heart disease risk: a prospective population study. Arch Intern Med. 2009; 169(15):1424-9. DOI: 10.1001/archinternmed.2009.234. View

La Sala L, Pontiroli A . Prevention of Diabetes and Cardiovascular Disease in Obesity. Int J Mol Sci. 2020; 21(21). PMC: 7663329. DOI: 10.3390/ijms21218178. View

Manson J, Shufelt C, Robins J . The Potential for Postrandomization Confounding in Randomized Clinical Trials. JAMA. 2016; 315(21):2273-4. DOI: 10.1001/jama.2016.3676. View

Laakso M, Fernandes Silva L . Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne). 2023; 14:1239335. PMC: 10546337. DOI: 10.3389/fendo.2023.1239335. View

Shi J, Liu Y, Liu Y, Li Y, Qiu S, Bai Y . Association between ApoE polymorphism and hypertension: A meta-analysis of 28 studies including 5898 cases and 7518 controls. Gene. 2018; 675:197-207. DOI: 10.1016/j.gene.2018.06.097. View

Sarwar N, Gao P, Kondapally Seshasai S, Gobin R, Kaptoge S, Di Angelantonio E . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. PMC: 2904878. DOI: 10.1016/S0140-6736(10)60484-9. View

10.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. DOI: 10.1007/BF00280883. View

11.

Xie W, Zheng F, Yan L, Zhong B . Cognitive Decline Before and After Incident Coronary Events. J Am Coll Cardiol. 2019; 73(24):3041-3050. DOI: 10.1016/j.jacc.2019.04.019. View

12.

Huang Y, Mahley R . Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis. 2014; 72 Pt A:3-12. PMC: 4253862. DOI: 10.1016/j.nbd.2014.08.025. View

13.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

14.

Manson J, Chlebowski R, Stefanick M, Aragaki A, Rossouw J, Prentice R . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-68. PMC: 3963523. DOI: 10.1001/jama.2013.278040. View

15.

Curb J, McTiernan A, Heckbert S, Kooperberg C, Stanford J, Nevitt M . Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003; 13(9 Suppl):S122-8. DOI: 10.1016/s1047-2797(03)00048-6. View

16.

Frostegard J . Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013; 11:117. PMC: 3658954. DOI: 10.1186/1741-7015-11-117. View

17.

Anthopoulos P, Hamodrakas S, Bagos P . Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol Genet Metab. 2010; 100(3):283-91. DOI: 10.1016/j.ymgme.2010.03.008. View

18.

Kruit J, Wijesekara N, Manning Fox J, Dai X, Brunham L, Searle G . Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 2011; 60(12):3186-96. PMC: 3219942. DOI: 10.2337/db11-0081. View

19.

Kuhel D, Konaniah E, Basford J, McVey C, Goodin C, Chatterjee T . Apolipoprotein E2 accentuates postprandial inflammation and diet-induced obesity to promote hyperinsulinemia in mice. Diabetes. 2012; 62(2):382-91. PMC: 3554349. DOI: 10.2337/db12-0390. View

20.

Santos-Ferreira C, Baptista R, Oliveira-Santos M, Costa R, Moura J, Goncalves L . Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study. J Lipids. 2019; 2019:1698610. PMC: 6702854. DOI: 10.1155/2019/1698610. View